Evidence map›Paper›PMID 34589393›Full record

ReviewActa pharmaceutica Sinica. B2021

Integrins as attractive targets for cancer therapeutics.

Meng Li, Ying Wang, Mengwei Li, Xuezhen Wu, Sarra Setrerrahmane, Hanmei Xu

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed
27.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 230 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Experimental study of [EJNMMI research · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Meng LiKey Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102629, China.
Ying WangState Key Laboratory of Natural Medicines, Ministry of Education, the Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation of Jiangsu Province, Department of Marine Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Mengwei LiState Key Laboratory of Natural Medicines, Ministry of Education, the Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation of Jiangsu Province, Department of Marine Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Xuezhen WuAffiliated Hospital of Chifeng College, Inner Mongolia Autonomous Region 024005, China.
Sarra SetrerrahmaneState Key Laboratory of Natural Medicines, Ministry of Education, the Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation of Jiangsu Province, Department of Marine Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Hanmei XuState Key Laboratory of Natural Medicines, Ministry of Education, the Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation of Jiangsu Province, Department of Marine Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
State Key Laboratory of Natural MedicineChifeng University · CNChina Pharmaceutical University · CNNational Institutes for Food and Drug Control · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Integrins are transmembrane receptors that have been implicated in the biology of various human physiological and pathological processes. These molecules facilitate cell-extracellular matrix and cell-cell interactions, and they have been implicated in fibrosis, inflammation, thrombosis, and tumor metastasis. The role of integrins in tumor progression makes them promising targets for cancer treatment, and certain integrin antagonists, such as antibodies and synthetic peptides, have been effectively utilized in the clinic for cancer therapy. Here, we discuss the evidence and knowledge on the contribution of integrins to cancer biology. Furthermore, we summarize the clinical attempts targeting this family in anti-cancer therapy development.

Indexed as

ADAMs, adisintegrin and metalloproteasesAJ, adherens junctionsAntagonistsCAFs, cancer-associated fibroblastsCAR, chimeric antigen receptorClinical trialCRC, colorectal cancerCSC, cancer stem cellECM, extracellular matrixEGFR, epidermal growth factor receptorEMT, epithelial–mesenchymal transitionERK, extracellular regulated kinaseExtracellular matrixFAK, focal adhesion kinaseFDA, U.S. Food and Drug AdministrationHIF-1α, hypoxia-inducible factor-1αHUVECs, human umbilical vein endothelial cellsICAMs, intercellular adhesion moleculesIGFR, insulin-like growth factor receptorIMD, integrin-mediated deathIntegrinsJNK, c-Jun N-terminal kinase 16mAb, monoclonal antibodiesMAPK, mitogen-activated protein kinaseMMP2, matrix metalloprotease 2NF-κB, nuclear factor-κBNSCLC, non-small cell lung cancerPDGFR, platelet-derived growth factor receptorPI3K, phosphatidylinositol 3-kinaseRGD, Arg-Gly-AspRTKs, receptor tyrosine kinasesSAPKs, stress-activated MAP kinasessdCAR-T, switchable dual-receptor CAR-engineered TSDF-1, stromal cell-derived factor-1SH2, Src homology 2siRNA, small interference RNASTAT3, signal transducer and activator of transcription 3Targeted drugTCGA, The Cancer Genome AtlasTICs, tumor initiating cellsTNF, tumor necrosis factorTumor progressionuPA, urokinase-type plasminogen activatorVCAMs, vascular cell adhesion moleculesVEGFR, vascular endothelial growth factor receptor

Identifiers

PMID34589393
PMCPMC8463276
OpenAlexW3153769500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.